U.S body says gene therapy may be more cost effective for spinal muscular atrophy

Biogen Inc’s Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG’s experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said on Thursday.

Original source: http://feeds.reuters.com/~r/reuters/INhealth/~3/ESVq7gwkMCg/u-s-body-says-gene-therapy-may-be-more-cost-effective-for-spinal-muscular-atrophy-idINKCN1OK03K

Related Posts